LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Home・Aktien・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

36.52 2.33

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

35.66

Max

37.88

Schlüsselkennzahlen
By Trading Economics
Einkommen	-20M -85M
Gewinnspanne	-867.293
Angestellte	316
EBITDA	-21M -94M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+52.83% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	11. Nov. 2025

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	158M 2.8B
Vorheriger Eröffnungskurs	34.19
Vorheriger Schlusskurs	36.52

Nachrichtenstimmung

By Acuity

50%

167 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

34.81 / 38.24 Unterstützung & Widerstand

Xenon Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Sept. 2025, 23:01 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17. Sept. 2025, 22:48 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17. Sept. 2025, 21:59 UTC

Ergebnisse

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17. Sept. 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17. Sept. 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17. Sept. 2025, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17. Sept. 2025, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17. Sept. 2025, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17. Sept. 2025, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17. Sept. 2025, 22:18 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17. Sept. 2025, 21:00 UTC

Ergebnisse

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17. Sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. Sept. 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Sept. 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17. Sept. 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17. Sept. 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17. Sept. 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17. Sept. 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17. Sept. 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Sept. 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17. Sept. 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17. Sept. 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17. Sept. 2025, 17:15 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17. Sept. 2025, 17:06 UTC

Akquisitionen, Fusionen, Übernahmen

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17. Sept. 2025, 16:51 UTC

Ergebnisse

Correct: Exor 1H Net Loss -EUR624M

17. Sept. 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Sept. 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17. Sept. 2025, 16:25 UTC

Ergebnisse

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17. Sept. 2025, 16:23 UTC

Ergebnisse

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Peer-Vergleich

Kursveränderung

Xenon Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

52.83% Vorteil

12-Monats-Prognose

Durchschnitt 54.5 USD 52.83%

Hoch 65 USD

Tief 48 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Xenon Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

Buy

Halten

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Xenon Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

34.81 / 38.24Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Stimmung

By Acuity

167 / 371 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.